About MS Views and News

Within this blog you will find thousands of valuable MS related articles and resources which will enable you to learn and feel empowered with key Multiple Sclerosis information.

Please Visit our Website: www.msvn.org and our Social media platforms: Facebook, Twitter, and Instagram. Each providing knowledge for those affected by MS. *

From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.

Be empowered with MS news. CLICK HERE -to Subscribe forThe MS BEACON eNewsletter

Plus, learn from the MS Views and News Learning Channel on YouTube: www.youtube.com/msviewsandnews:


Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, February 16, 2019

Sephin1 May Provide Neuroprotective Benefits for Multiple Sclerosis

FEBRUARY 12, 2019
Erica Slaughter

A recently published study shows that modulation of the integrated stress response (ISR) may be an effective neuroprotective therapy for multiple sclerosis (MS) patients with Sephin1 treatment. Sephin1 was shown to protect oligodendrocytes, axons, and myelin, which is correlated with a prolonged ISR, as well as reduced central nervous system (CNS) inflammation, in MS mouse models with chronic experimental autoimmune encephalomyelitis (EAE).

The pathological hallmarks of MS are the destruction of oligodendrocytes, the myelin-producing cells of the CNS, with resultant demyelination and axonal degeneration. The ISR, a cellular protective response that is activated by a variety of cytotoxic insults, has been shown to be triggered in oligodendrocytes by CNS inflammation.

The findings, from investigators at the University of Chicago, further demonstrate that Sephin1 treatment of chronic EAE mice significantly delays disease onset and reduces the number of inflammatory CD3+ T cells and inflammatory cytokine production within the CNS, without affecting the peripheral immune response. The team hypothesized that Sephin1 could lead to better clinical outcomes in MS patients as a safe, neuroprotective drug.

When used in combination with interferon beta-1a (IFN-b), the decrease in clinical disease development in chronic EAE mice was even more pronounced, and may produce better therapeutic outcomes than with either Sephin1 or IFN-b alone. Investigators found that onset of disease was significantly delayed with combination therapy compared to IFN-b treatment alone, which did not affect the onset of disease.

Combination treatment also seemed to affect disease course, as chronic EAE mice treated with both Sephin1 and IFN-b reached the peak of disease much later than those treated with IFN-b alone. Brian Popko, PhD, Jack Miller Professor of Neurological Disorders, and Director, The University of Chicago Center for Peripheral Neuropathy, speculated to MD Magazine® that Sephin1’s benefits would be complementary to current immunomodulatory therapies, as it acts on the distinct ISR pathway, and with oligodendrocyte protection.

“This is supported by the studies presented in our manuscript that showed that Sephin1 and interferon beta provided additive therapeutic benefit to a mouse model inflammatory demyelination,” Popko explained.

Sephin1Similar in mechanism of action to Sephin1, Guanabenz was investigated in a clinical trial for its safety and tolerability in patients with MS (NCT02423083). The trial has since been terminated due to side effects. The anti-hypertensive drug had previously been shown to successfully delay disease onset and attenuate clinical symptoms in chronic EAE mice. Guanabenz, an alpha-2 adrenergic receptor agonist, is characterized by its lowering of blood pressure, Popko said, as well as its propensity to create drowsiness, lethargy, and additional adverse effects in patients.

“Sephin1 does not display these adrenergic effects, such that it should be much more tolerable,” he said. “Nevertheless, it will, of course, need to go through safety testing before being introduced to MS patients.”

Popko and colleagues are presently investigating the potential of Sephin1 to provide protection to remyelinating oligodendrocytes against inflammation in EAE mice.

“We are hopeful that Sephin1, which prolongs the integrated stress response, will provide protection to remyelinating oligodendrocytes in the presence of an inflammatory environment,” Popko said. “We are testing this in mouse models of demyelination that display an inflammatory environment during CNS remyelination.”

Such results should be available to the team by this summer.

Article Provided by:  #MSViewsandNews

Friday, February 15, 2019

Prevalence of MS More Than Doubles Estimate

A new study funded by the National MS Society has confirmed that nearly one million people are living with MS in the United States, more than twice the original estimate from a previous study. This breakthrough is a pivotal moment in the MS movement as a scientifically sound measure of prevalence helps us better understand the disease and its impact. With twice as many people are living with MS, solutions for MS are now twice as important.
In addition to the main paper outlining these results, two companion papers providing background information on prevalence in the U.S. and reviewing the study methods were also published in the February 15, 2019, online issue of Neurology®, the medical journal of the American Academy of Neurology.

Read about the Study


To receive The MS BEACON, e-Newsletter, Click here
CLICK BOX to SUBSCRIBE to our MS Learning Channel on YouTube: 
Click Red Box on banner to opt-in
Article Provided by:  #MSViewsandNews

Landmark Study Estimates Nearly 1 Million in the U.S. Have Multiple Sclerosis

February 15, 2019
  • A study by leading experts estimates that in 2017, nearly 1 million adults (up to 913,925) were living with MS in the United States. This is more than twice the previously reported number from a national study in 1975 and subsequent updates.
  • The study was launched and supported by the National MS Society with the goal of determining the best way to develop a scientifically sound and economically feasible estimate of the number of people in the U.S. who have MS.
  • Having an updated prevalence estimate will allow a better understanding of the needs of people with MS and the economic burdens imposed by the disease on families and society. It will be a starting point for researchers to understand if MS is increasing, or if there are MS geographic clusters that may hold clues to new risk factors that trigger MS. These data will also help ensure that the National MS Society is able to connect to and support all people affected by MS.
  • The team published its findings in three papers early online on February 15, 2019 in the journal Neurology (follow links below).
“This study tells us many things, but one thing in particular -- twice as many people need a cure,” said Cyndi Zagieboylo, President and CEO of the National Multiple Sclerosis Society. “We must do more. We need to raise more money to fund more research; we need to fund the programs and services that help people with MS live their best lives; and we need to make sure the voices of people living with MS are heard and their rights to have quality, affordable health care are protected.” 
Background: In the United States, there has not been a scientifically sound, national study of prevalence since 1975. Additionally, MS incidence (the number of people newly diagnosed with MS within a given period of time) and prevalence (the number of people living with a diagnosis of MS within a given period of time) are not consistently reported or tracked in the U.S., and there is no government requirement to do so. 
The National MS Society has been advocating for a national neurological disease surveillance system that would provide deeper information about the prevalence and impacts of MS and other disorders. In 2016, Congress finally passed the 21st Century Cures Act, which authorized the creation of the National Neurological Conditions Surveillance System. In 2018, funding was provided for its implementation by the Centers for Disease Control and Prevention (CDC).


Article Provided by:  #MSViewsandNews

How does trigeminal neuralgia affect the body?

The effect of #trigeminal neuralgia on the body depends on what is causing the condition. While the cause cannot always be determined, it is commonly the result of pressure on the trigeminal nerve. When something like a vein or artery presses against the nerve, which can cause pain impulses or block impulses; the result is pain or slight numbness. The same result can also happen if you develop a tumor near the trigeminal nerve, but this is much less common. A condition like multiple sclerosis can also result in trigeminal neuralgia, by causing damage to the myelin sheath that protects the nerve.


The term neuralgia is used to describe pain that radiates along the path of a nerve. In some cases the cause is unknown, but the condition can be caused by some drugs, irritation from chemicals, kidney problems, diabetes, infections, pressure on nerves or from an injury. Trigeminal neuralgia is the most common type and involves facial pain. Neuralgia can occur at any age, but it is most common among the elderly. Neuralgia is not life-threatening, but the pain can be severe. A pain specialist can suggest ways to control the pain.


To receive The MS BEACON, e-Newsletter, Click here
Article Provided by:  #MSViewsandNews

You Can Lift Your Legs & Reduce Your MS Hug Plus other Free MS Exercise Guides

 KEY MS exercises to help you:

- Lift your legs higher
- Reduce foot drop
- Reduce your painful MS Hug. 

Grab your free exercise guide today, and start training your body to walk better, breathe better, and move stronger.   Click Here

Visit the MS Gym Youtube Channel found here


To receive The MS BEACON, e-Newsletter, Click here
CLICK BOX to SUBSCRIBE to our MS Learning Channel on YouTube: 
Click Red Box on banner to opt-in
Article Provided by:  #MSViewsandNews

Wednesday, February 13, 2019

Masterswitch discovered in body's immune system


immune system

Scientists have discovered a critical part of the body's immune system with potentially major implications for the treatment of some of the most devastating diseases affecting humans.

Professor Graham Lord, from The University of Manchester, led the study, which could translate into treatments for autoimmune diseases including Cancer, Diabetes, Multiple Sclerosis and Crohn's Disease within a few years.

It is published in the Journal of Clinical Investigation today.

The discovery of the molecular pathway regulated by a tiny molecule—known as microRNA-142—is a major advance in our understanding of the immune system.

The 10-year-study found that microRNA-142 controls Regulatory T cells, which modulate the immune system and prevent autoimmune disease. It is, they found, the most highly expressed regulator in the immune system.

Professor Lord, led the research while at Kings College London in collaboration with Professor Richard Jenner at UCL.

And according to Professor Lord, the discovery could be translated into a viable drug treatment within a few years.

He said: "Autoimmune diseases often target people in the prime of their life creating a significant socio-economic burden on them. Sometimes, the effect can be devastating, causing terrible hardship and suffering.

"But these findings represent a significant step forward in the understanding of the immune system and we believe many people worldwide may benefit."

If the activity of Regulatory T cells is too low, this can cause other immune cells to attack our own body tissues. If these Regulatory T cells are too active, this leads to suppression of immune responses and can allow cancers to evade the immune system.

So being able to control them is a major step forward in our ability to control- and harness—the therapeutic power of the immune system.

Professor Richard Jenner from UCL, who led the computational side of the project, said that: "We were able to trace the molecular fingerprints of this molecule across other genes to determine how it acted as such a critical regulator."

Professor Lord, now Vice President and Dean of the Faculty of Biology, Medicine and Health at The University of Manchester, added: "Scientists over the past decade or so have developed therapies which are able to modulate different pathways of the immune system. We hope that this new discovery will lead to the development of new ways to treat autoimmunity, infectious diseases and cancer and we are incredibly excited about where this may lead."

Read more

Article Provided by:  #MSViewsandNews

Monday, February 11, 2019

2019 MS Neuro TV Webinar Series Calendar


and click here to view our MS Neuro TV archives